Clinical Trial Update: Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial studying perioperative Remodulin in liver transplant recipients was withdrawn at the Phase 2/3 stage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Liver Transplant | Phase 2, Phase 3 | Status: WITHDRAWN